MATOS Masters in Thoracic Oncology Summit 2023

 Topics:

• ALK in Front Line Therapy Second or Third Generation TKI Inhibitors What Can Help Us to Choose the Best Therapeutic Agent.mp4
• Anti-CEACAM and ROR ADCs.mp4
• Best Approaches for First Line EGFRm NSCLC.mp4
• Best Surgical Approaches for Stage III NSCLC.mp4
• Biomarkers for Perioperative Immunotherapy.mp4
• Brain Radiotherapy in Small Cell Lung Cancer When.mp4
• Cellular Therapies in NSCLC Is it feasible.mp4
• ctDNA Analyses in Early Detection Methylation, Proteomics and Other Efforts for Early Lung Cancer Detection.mp4
• Deciphering the Mechanism of Resistance to First Generation KRAS Inhibitors.mp4
• Developing New Anti-CTL4s for NSCLC Is There Any Role.mp4
• Early Stage Resectable Lung Cancer Adjuvant Immunotherapy.mp4
• Exon 20 and Uncommon EGFR Sensitive Mutations.mp4
• Frontline What are We Adding to Checkpoint Inhibitors and Chemotherapy.mp4
• Future Challenges for lmmunotherapy in the Fight Against NSCLC.mp4
• Health Care Disparities in Lung Cancer Genomic Profiling Has Precision Oncology Widened the Gap.mp4
• HER-3 as a New Target in NSCLC.mp4
• HER2 Tx in Advanced NSCLC From TKls to ADCs.mp4
• How to Rescue Patients from Osimertinib Resistance.mp4
• How to Start a Lung Cancer Screening Program.mp4
• Improving Targeted Therapies for Patients with Lung Cancers Where are the gaps and ways to fill them.mp4
• KRAS mutant NSCLC What is the Standard of Care Now.mp4
• Lack of Equity in Clinical Outcomes in Blacks and Hispanics with NSCLC.mp4
• Limited Stage SCLC 2023.mp4
• Management of LA-NSCLC in Pts with PD-L1 – 1% or Oncogenic Drivers.mp4
• Mechanisms of Resistance to ALK Inhibitors.mp4
• Minimal Residual Disease as Detected by Liquid Biopsy Where are We Going.mp4
• MRD to Decide Perioperative Management in the Era of Immuno-Oncology.mp4
• Neoadjuvant Immunotherapy Position.mp4
• Novel Therapies for Thymic Malignancies.mp4
• NRG1 as a Target in NSCLC.mp4
• Optimal Management of Extensive SCLC (1st and 2nd Line).mp4
• Overcoming T-Cell Exhaustion.mp4
• Pan-KRAS Inhibitors Where are We Going.mp4
• PARP Inhibitors in SCLC.mp4
• Predictive Biomarkers in Small Cell Lung Carcinoma.mp4
• Radiation Induced Immune Responses in NSCLC.mp4
• RET and NTRK The Good, The Bad, The Ugly…. and What’s Coming Up.mp4
• Role of Interleukins to Improve Efficacy of Immunotherapy.mp4
• Role of Radiotherapy in TIME Good Bad Don’t know.mp4
• ROS1 and BRAf Inhibitors New Developments.mp4
• Stage III Non-Surgical NSCLC Optimal Radiation Therapy Treatment Approach.mp4
• Strategies to Target Minimal Residual Disease in Lung Cancer.mp4
• Surgery for Malignant Pleural Mesothelioma.mp4
• Systemic Therapies for Mesothelioma.mp4
• The Importance of TIME in Cancer Treatment How to Target It.mp4
• The New Role of Microbiome in Lung Cancer Immunotherapy.mp4
• The Role of Co-Mutations in Immunotherapy Response in NSCLC.mp4
• The Role of SHP-2 Inhibitors Alone or in Combination.mp4
• TROP-2 and AXL as Targets in NSCLC.mp4
• Updates in Bispecific Antibodies in NSCLC.mp4
• What Comes After Immunotherapy Failure in Terms of More Immunomodulation.mp4
• What’s After PACIFIC Can We Raise the Bar.mp4